The genetics of age-related macular degeneration (AMD) - Novel targets for designing treatment options?

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 95, Issue , 2015, Pages 194-202

  Grassmann, Felix ^a   Fauser, Sascha ^b   Weber, Bernhard H F ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Age related macular degeneration (AMD); Clinical trials; Complement cascade; Genetic predisposition; Geographic atrophy; Neovascular AMD; Therapeutic approaches

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; NEUROPROTECTIVE AGENT; RANIBIZUMAB; VASCULOTROPIN;

AGE RELATED MACULAR DEGENERATION; ARTICLE; CLINICAL TRIAL (TOPIC); COMPLEMENT SYSTEM; DISEASE COURSE; EXPERIMENTAL THERAPY; EXTRACELLULAR MATRIX; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEREDITY; HUMAN; INFLAMMATION; KNOWLEDGE; META ANALYSIS (TOPIC); NONHUMAN; PHOTODYNAMIC THERAPY; RISK ASSESSMENT; ANIMAL; DRUG DESIGN; GENETIC PREDISPOSITION; GENETICS; MACULAR DEGENERATION; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; RISK; SEVERITY OF ILLNESS INDEX;

ANIMALS; DISEASE PROGRESSION; DRUG DESIGN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MACULAR DEGENERATION; MOLECULAR TARGETED THERAPY; RISK; SEVERITY OF ILLNESS INDEX;

EID: 84943658875     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.04.039     Document Type: Article

References (97)

1. D. Pascolini, and S.P. Mariotti Global estimates of visual impairment: 2010 Br. J. Ophthalmol. 96 2012 614 618
2. F. Jonasson, A. Arnarsson, G. Eiríksdottir, T.B. Harris, L.J. Launer, S.M. Meuer, and et al. Prevalence of age-related macular degeneration in old persons: age, gene/environment Susceptibility Reykjavik Study Ophthalmology 118 2011 825 830
3. R. Klein, B.E.K. Klein, M.D. Knudtson, S.M. Meuer, M. Swift, and R.E. Gangnon Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study Ophthalmology 114 2007 253 262
4. M. Hermann, A. Caramoy, S. Schröder, K. Dröge, B. Kirchhof, and S. Fauser Prevalence of age-related macular degeneration in persons aged 90 years and older in Cologne Acta Ophthalmol. 90 2012 e500 e501
5. J. Dreyhaupt, U. Mansmann, M. Pritsch, J. Dolar-Szczasny, A. Bindewald, and F.G. Holz Modelling the natural history of geographic atrophy in patients with age-related macular degeneration Ophthalmic Epidemiol. 12 2005 353 362
6. S. Rofagha, R.B. Bhisitkul, D.S. Boyer, S.R. Sadda, and K. Zhang Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP) Ophthalmology 120 2013 2292 2299
7. J.R. Evans Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration Cochrane Database Syst. Rev. 2006 CD000254
8. R. Van Leeuwen, S. Boekhoorn, J.R. Vingerling, J.C.M. Witteman, C.C.W. Klaver, A. Hofman, and et al. Dietary intake of antioxidants and risk of age-related macular degeneration JAMA 294 2005 3101 3107
9. T. Ristau, L. Ersoy, Y. Lechanteur, A.I. den Hollander, M.R. Daha, M. Hahn, and et al. Allergy is a protective factor against age-related macular degeneration Invest. Ophthalmol. Vis. Sci. 55 2014 210 214
10. L.G. Fritsche, W. Chen, M. Schu, B.L. Yaspan, Y. Yu, G. Thorleifsson, and et al. Seven new loci associated with age-related macular degeneration Nat. Genet. 45 2013 433 439 439e1-439e2
11. M.E. Pennesi, M. Neuringer, and R.J. Courtney Animal models of age related macular degeneration Mol. Aspects Med. 33 2012 487 509
12. D. Welter, J. MacArthur, J. Morales, T. Burdett, P. Hall, H. Junkins, and et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations Nucleic Acids Res. 42 2014 D1001 D1006
13. D. Yekutieli, and Y. Benjamini The control of the false discovery rate in multiple testing under dependency Ann. Stat. 29 2001 1165 1188
14. D.L. Streiner, and G.R. Norman Correction for multiple testing: is there a resolution? Chest 140 2011 16 18
15. J.M. Seddon, J. Cote, W.F. Page, S.H. Aggen, and M.C. Neale The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences Arch. Ophthalmol. 123 2005 321 327
16. M. Gatz, C.A. Reynolds, L. Fratiglioni, B. Johansson, J.A. Mortimer, S. Berg, and et al. Role of genes and environments for explaining Alzheimer disease Arch. Gen. Psychiatry 63 2006 168 174
17. C. Tysk, E. Lindberg, G. Järnerot, and B. Flodérus-Myrhed Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking Gut 29 1988 990 996
18. A.J. Walley, A.I.F. Blakemore, and P. Froguel Genetics of obesity and the prediction of risk for health Hum. Mol. Genet. 15 2006 (Spec No: R124-30)
19. M.J. Kjeldsen, K.O. Kyvik, K. Christensen, and M.L. Friis Genetic and environmental factors in epilepsy: a population-based study of 11900 Danish twin pairs Epilepsy Res. 44 2001 167 178
20. R. Allikmets, N.F. Shroyer, N. Singh, J.M. Seddon, R.A. Lewis, P.S. Bernstein, and et al. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration Science 277 1997 1805 1807
21. A. Rivera, K. White, H. Stöhr, K. Steiner, N. Hemmrich, T. Grimm, and et al. A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene in Stargardt disease and age-related macular degeneration Am. J. Hum. Genet. 67 2000 800 813
22. E.M. Stone, A.R. Webster, K. Vandenburgh, L.M. Streb, R.R. Hockey, A.J. Lotery, and et al. Allelic variation in ABCR associated with Stargardt disease but not age-related macular degeneration Nat. Genet. 20 1998 328 329
23. L.G. Fritsche, M. Fleckenstein, B.S. Fiebig, S. Schmitz-Valckenberg, A. Bindewald-Wittich, C.N. Keilhauer, and et al. A subgroup of age-related macular degeneration is associated with mono-allelic sequence variants in the ABCA4 gene Invest. Ophthalmol. Vis. Sci. 53 2012 2112 2118
24. C.C.W. Klaver, M. Kliffen, C.M. Van Duijn, A. Hofman, M. Cruts, D.E. Grobbee, and et al. Genetic association of apolipoprotein E with age-related macular degeneration Ophthalmic Res. 1998 200 206
25. S. Zareparsi, A.C. Reddick, K.E.H. Branham, K.B. Moore, L. Jessup, S. Thoms, and et al. Association of apolipoprotein E alleles with susceptibility to age-related macular degeneration in a large cohort from a single center Invest. Ophthalmol. Vis. Sci. 45 2004 1306 1310
26. P.N. Baird, A.J. Richardson, L.D. Robman, P.N. Dimitrov, G. Tikellis, C.A. McCarty, and et al. Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD) Hum. Mutat. 27 2006 337 342
27. G.J. McKay, G. Silvestri, U. Chakravarthy, S. Dasari, L.G. Fritsche, B.H. Weber, and et al. Variations in apolipoprotein E frequency with age in a pooled analysis of a large group of older people Am. J. Epidemiol. 173 2011 1357 1364
28. R.J. Klein, C. Zeiss, E.Y. Chew, J. Tsai, R.S. Sackler, C. Haynes, and et al. Complement factor H polymorphism in age-related macular degeneration Science 308 2005 385 389
29. A. Rivera, S.A. Fisher, L.G. Fritsche, C.N. Keilhauer, P. Lichtner, T. Meitinger, and et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk Hum. Mol. Genet. 14 2005 3227 3236
30. J. Jakobsdottir, Y.P. Conley, D.E. Weeks, T.S. Mah, R.E. Ferrell, and M.B. Gorin Susceptibility genes for age-related maculopathy on chromosome 10q26 Am. J. Hum. Genet. 77 2005 389 407
31. G.S. Hageman, D.H. Anderson, L.V. Johnson, L.S. Hancox, A.J. Taiber, L.I. Hardisty, and et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration Proc. Natl. Acad. Sci. USA 102 2005 7227 7232
32. K.L. Spencer, L.M. Olson, B.M. Anderson, N. Schnetz-Boutaud, W.K. Scott, P. Gallins, and et al. C3 R102G polymorphism increases risk of age-related macular degeneration Hum. Mol. Genet. 17 2008 1821 1824
33. L.G. Fritsche, R.N. Fariss, D. Stambolian, G.R. Abecasis, C.A. Curcio, and A. Swaroop Age-related macular degeneration: genetics and biology coming together Annu. Rev. Genomics Hum. Genet. 15 2014 151 171
34. M.B. Gorin Genetic insights into age-related macular degeneration: controversies addressing risk, causality, and therapeutics Mol. Aspects Med. 33 2012 467 486
35. B.H.F. Weber, P. Charbel Issa, D. Pauly, P. Herrmann, F. Grassmann, and F.G. Holz The role of the complement system in age-related macular degeneration Dtsch. Arztebl. Int. 111 2014 133 138
36. S. Raychaudhuri, O. Iartchouk, K. Chin, P.L. Tan, A.K. Tai, S. Ripke, and et al. A rare penetrant mutation in CFH confers high risk of age-related macular degeneration Nat. Genet. 43 2011 1232 1236
37. B. Gold, J.E. Merriam, J. Zernant, L.S. Hancox, A.J. Taiber, K. Gehrs, and et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration Nat. Genet. 38 2006 458 462
38. X. Zhan, D.E. Larson, C. Wang, D.C. Koboldt, Y.V. Sergeev, R.S. Fulton, and et al. Identification of a rare coding variant in complement 3 associated with age-related macular degeneration Nat. Genet. 45 2013 1375 1379
39. J.M. Seddon, Y. Yu, E.C. Miller, R. Reynolds, P.L. Tan, S. Gowrisankar, and et al. Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration Nat. Genet. 45 2013 1366 1370
40. H. Helgason, P. Sulem, M.R. Duvvari, H. Luo, G. Thorleifsson, H. Stefansson, and et al. A rare nonsynonymous sequence variant in C3 is associated with high risk of age-related macular degeneration Nat. Genet. 45 2013 1371 1374
41. J.P.H. Van de Ven, S.C. Nilsson, P.L. Tan, G.H.S. Buitendijk, T. Ristau, F.C. Mohlin, and et al. A functional variant in the CFI gene confers a high risk of age-related macular degeneration Nat. Genet. 45 2013 813 817
42. W. Chen, D. Stambolian, A.O. Edwards, K.E. Branham, M. Othman, J. Jakobsdottir, and et al. Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration Proc. Natl. Acad. Sci. USA 107 2010 7401 7406
43. Y. Yu, T.R. Bhangale, J. Fagerness, S. Ripke, G. Thorleifsson, P.L. Tan, and et al. Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration Hum. Mol. Genet. 20 2011 3699 3709
44. L.G. Fritsche, N. Lauer, A. Hartmann, S. Stippa, C.N. Keilhauer, M. Oppermann, and et al. An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD) Hum. Mol. Genet. 19 2010 4694 4704
45. S.L. Edwards, J. Beesley, J.D. French, and A.M. Dunning Beyond GWASs: illuminating the dark road from association to function Am. J. Hum. Genet. 93 2013 779 797
46. M.L. Klein, P.J. Francis, F.L. Ferris, S.C. Hamon, and T.E. Clemons Risk assessment model for development of advanced age-related macular degeneration Arch. Ophthalmol. 129 2011 1543 1550
47. J.M. Seddon, R. Reynolds, Y. Yu, M.J. Daly, and B. Rosner Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors Ophthalmology 118 2011 2203 2211
48. G.H.S. Buitendijk, E. Rochtchina, C. Myers, C.M. van Duijn, K.E. Lee, B.E.K. Klein, and et al. Prediction of age-related macular degeneration in the general population: the Three Continent AMD Consortium Ophthalmology 120 2013 2644 2655
49. G.S. Hageman, K. Gehrs, S. Lejnine, A.T. Bansal, M.M. Deangelis, R.H. Guymer, and et al. Clinical validation of a genetic model to estimate the risk of developing choroidal neovascular age-related macular degeneration Hum. Genomics 5 2011 420 440
50. F. Grassmann, I.M. Heid, and B.H.F. Weber Genetic risk models in age-related macular degeneration Adv. Exp. Med. Biol. 801 2014 291 300
51. F. Grassmann, L.G. Fritsche, C.N. Keilhauer, I.M. Heid, and B.H.F. Weber Modelling the genetic risk in age-related macular degeneration PLoS One 7 2012 e37979
52. C.J. Hammond, A.R. Webster, H. Snieder, A.C. Bird, C.E. Gilbert, and T.D. Spector Genetic influence on early age-related maculopathy: a twin study Ophthalmology 109 2002 730 736
53. E.G. Holliday, A.V. Smith, B.K. Cornes, G.H.S. Buitendijk, R.A. Jensen, X. Sim, and et al. Insights into the genetic architecture of early stage age-related macular degeneration: a genome-wide association study meta-analysis PLoS One 8 2013 e53830
54. L.G. Fritsche, T. Loenhardt, A. Janssen, S.a. Fisher, A. Rivera, C.N. Keilhauer, and et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA Nat. Genet. 40 2008 892 896
55. U. Friedrich, C.a. Myers, L.G. Fritsche, A. Milenkovich, A. Wolf, J.C. Corbo, and et al. Risk- and non-risk-associated variants at the 10q26 AMD locus influence ARMS2 mRNA expression but exclude pathogenic effects due to protein deficiency Hum. Mol. Genet. 20 2011 1387 1399
56. A.W. Scott, and S.B. Bressler Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration Curr. Opin. Ophthalmol. 24 2013 190 196
57. E.S. Gragoudas, A.P. Adamis, E.T. Cunningham, M. Feinsod, and D.R. Guyer Pegaptanib for neovascular age-related macular degeneration N. Engl. J. Med. 351 2004 2805 2816
58. D.M. Brown, P.K. Kaiser, M. Michels, G. Soubrane, J.S. Heier, R.Y. Kim, and et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration N. Engl. J. Med. 355 2006 1432 1444
59. D.F. Martin, M.G. Maguire, S.L. Fine, G. Ying, G.J. Jaffe, J.E. Grunwald, and et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
60. U. Chakravarthy, S.P. Harding, C.A. Rogers, S.M. Downes, A.J. Lotery, L.A. Culliford, and et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial Lancet 382 2013 1258 1267
61. T. Ristau, B. Kirchhof, and S. Fauser Antisepsis with polyhexanide is effective against endophthalmitis after intravitreal injections Acta Ophthalmol. 92 2014 e494 e496
62. S.E. Quaggin Turning a blind eye to anti-VEGF toxicities J. Clin. Invest. 122 2012 3849 3851
63. T. Kurihara, P.D. Westenskow, S. Bravo, E. Aguilar, and M. Friedlander Targeted deletion of Vegfa in adult mice induces vision loss J. Clin. Invest. 122 2012 4213 4217
64. F.G. Holz, S. Schmitz-Valckenberg, and M. Fleckenstein Recent developments in the treatment of age-related macular degeneration J. Clin. Invest. 124 2014 1430 1438
65. M. Hanout, D. Ferraz, M. Ansari, N. Maqsood, S. Kherani, Y.J. Sepah, and et al. Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development Biomed. Res. Int. 2013 2013 830837
66. R.P. Casaroli-Marano, S. Alforja, J. Giralt, and M.E. Farah Epimacular brachytherapy for wet AMD: current perspectives Clin. Ophthalmol. 8 2014 1661 1670
67. R.L. Avery, A.A. Castellarin, N.C. Steinle, D.S. Dhoot, D.J. Pieramici, R. See, and et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD Br. J. Ophthalmol. 98 2014 1636 1641
68. C. Schmucker, Y.K. Loke, C. Ehlken, H.T. Agostini, L.L. Hansen, G. Antes, and et al. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review Br. J. Ophthalmol. 95 2011 308 317
69. L.H. Curtis, B.G. Hammill, K.A. Schulman, and S.W. Cousins Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration Arch. Ophthalmol. (Chicago, Ill 1960) 128 2010 1273 1279
70. V. Eremina, J.A. Jefferson, J. Kowalewska, H. Hochster, M. Haas, J. Weisstuch, and et al. VEGF inhibition and renal thrombotic microangiopathy N. Engl. J. Med. 358 2008 1129 1136
71. M.A. Zarbin, and P.J. Rosenfeld Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives Retina 30 2010 1350 1367
72. T. Ristau, C. Paun, L. Ersoy, M. Hahn, Y. Lechanteur, C. Hoyng, and et al. Impact of the common genetic associations of age-related macular degeneration upon systemic complement component C3d levels PLoS One 9 2014 e93459
73. M.P. Kawa, A. Machalinska, D. Roginska, and B. Machalinski Complement system in pathogenesis of AMD: dual player in degeneration and protection of retinal tissue J. Immunol. Res. 2014 2014 483960
74. D. Pauly, B.M. Nagel, J. Reinders, T. Killian, M. Wulf, S. Ackermann, and et al. A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples PLoS One 9 2014 e96371
75. Z. Yehoshua, C. Alexandre de Amorim Garcia Filho, R.P. Nunes, G. Gregori, F.M. Penha, A.A. Moshfeghi, and et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study Ophthalmology 121 3 2014 693 701
76. Y. Rahpeymai, M.A. Hietala, U. Wilhelmsson, A. Fotheringham, I. Davies, A.-K. Nilsson, and et al. Complement: a novel factor in basal and ischemia-induced neurogenesis EMBO J. 25 2006 1364 1374
77. J. Van Beek, O. Nicole, C. Ali, A. Ischenko, E.T. MacKenzie, A. Buisson, and et al. Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death Neuroreport 12 2001 289 293
78. T. Steiner, L. Francescut, S. Byrne, T. Hughes, A. Jayanthi, I. Guschina, and et al. Protective role for properdin in progression of experimental murine atherosclerosis PLoS One 9 2014 e92404
79. F. Grassmann, M. Fleckenstein, E.Y. Chew, T. Strunz, S. Schmitz-Valckenberg, A.P. Göbel, and et al. Clinical and genetic factors associated with progression of geographic atrophy lesions in age-related macular degeneration PLoS One 10 5 2015 e0126636
80. T. Montes, A. Tortajada, B.P. Morgan, S. Rodríguez de Córdoba, and C.L. Harris Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B Proc. Natl. Acad. Sci. USA 106 2009 4366 4371
81. R.S. Fife, G.W. Sledge, B.J. Roth, and C. Proctor Effects of doxycycline on human prostate cancer cells in vitro Cancer Lett. 127 1998 37 41
82. T. Krakauer, and M. Buckley Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines Antimicrob. Agents Chemother. 47 2003 3630 3633
83. G. Zahn, D. Vossmeyer, R. Stragies, M. Wills, C.G. Wong, K.U. Löffler, and et al. Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization Arch. Ophthalmol. 127 2009 1329 1335
84. K. Zhang, J.J. Hopkins, J.S. Heier, D.G. Birch, L.S. Halperin, T.A. Albini, and et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration Proc. Natl. Acad. Sci. USA 108 2011 6241 6245
85. E. Bertolotti, A. Neri, M. Camparini, C. Macaluso, and V. Marigo Stem cells as source for retinal pigment epithelium transplantation Prog. Retin. Eye Res. 42 2014 130 144
86. S.D. Schwartz, J.-P. Hubschman, G. Heilwell, V. Franco-Cardenas, C.K. Pan, R.M. Ostrick, and et al. Embryonic stem cell trials for macular degeneration: a preliminary report Lancet 379 2012 713 720
87. S.D. Schwartz, C.D. Regillo, B.L. Lam, D. Eliott, P.J. Rosenfeld, N.Z. Gregori, and et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies Lancet 385 9967 2015 509 516
88. H. Kamao, M. Mandai, S. Okamoto, N. Sakai, A. Suga, S. Sugita, and et al. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application Stem Cell Rep. 2 2014 205 218
89. Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 Arch. Ophthalmol. 119 2001 1417 1436
90. J.P.M. Wood, O. Shibeeb, M. Plunkett, R.J. Casson, and G. Chidlow Retinal damage profiles and neuronal effects of laser treatment: comparison of a conventional photocoagulator and a novel 3-nanosecond pulse laser Invest. Ophthalmol. Vis. Sci. 54 2013 2305 2318
91. R.H. Guymer, K.H. Brassington, P. Dimitrov, G. Makeyeva, M. Plunkett, W. Xia, and et al. Nanosecond-laser application in intermediate AMD: 12-month results of fundus appearance and macular function Clin. Exp. Ophthalmol. 42 2014 466 479
92. M.M. Nociari, G.L. Lehmann, A.E. Perez Bay, R.A. Radu, Z. Jiang, S. Goicochea, and et al. Beta cyclodextrins bind, stabilize, and remove lipofuscin bisretinoids from retinal pigment epithelium Proc. Natl. Acad. Sci. USA 111 2014 E1402 E1408
93. J.M. Seddon, R. Reynolds, J. Maller, J.a. Fagerness, M.J. Daly, and B. Rosner Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables Invest. Ophthalmol. Vis. Sci. 50 2009 2044 2053
94. H.P.N. Scholl, M. Fleckenstein, L.G. Fritsche, S. Schmitz-Valckenberg, A. Göbel, C. Adrion, and et al. CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD PLoS One 4 2009 e7418
95. M.L. Klein, F.L. Ferris, P.J. Francis, A.S. Lindblad, E.Y. Chew, S.C. Hamon, and et al. Progression of geographic atrophy and genotype in age-related macular degeneration Ophthalmology 117 2010 1554 1559 1559.e1
96. W.T. Wong, S. Dresner, F. Forooghian, T. Glaser, L. Doss, M. Zhou, and et al. Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial Invest. Ophthalmol. Vis. Sci. 54 2013 2941 2950
97. B. Falsini, M. Piccardi, A. Minnella, C. Savastano, E. Capoluongo, A. Fadda, and et al. Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration Invest. Ophthalmol. Vis. Sci. 51 2010 6118 6124